CYT 503
Alternative Names: CYT-503; iPSCs-derived GPC3 CAR NK therapy - Cytovia Therapeutics/National Cancer InstituteLatest Information Update: 28 May 2026
At a glance
- Originator Cytovia Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cancer; Solid tumours
- Discontinued Ovarian cancer
Most Recent Events
- 28 May 2026 No recent reports of development identified for preclinical development in Liver-cancer in USA (Parenteral)
- 28 May 2026 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 27 Apr 2022 Cytovia Therapeutics plans phase I/II trials